Table 1.
Demographic and clinical information of participants
| Inception |
Validation |
||||||
|---|---|---|---|---|---|---|---|
| 65 |
30 |
||||||
|
n |
rAAV |
nrAAV |
Rem |
HC |
rAAV |
nrAAV |
Rem |
| n | 33 | 4 | 20 | 8 | 19 | 3 | 8 |
| Age: yr median (IQR) | 57 (48, 64) | 44 (38, 51) | 63 (55, 71) | 47 (40, 54) | 67 (56, 73) | 50 (44, 58) | 64 (52, 68) |
| Sex: females (%) | 13 (39%) | 1 (25%) | 10 (50%) | 5 (63%) | 5 (26%) | 0 | 4 (50%) |
| Diagnosis | |||||||
| GPA: n, (%) | 21 (64%) | 4 (100%) | 11 (55%) | 10 (53%) | 2 (67%) | 5 (63%) | |
| MPA: n, (%) | 12 (36%) | 0 | 9 (45%) | 9 (47%) | 1 (33%) | 3 (37%) | |
| ANCA | |||||||
| anti-MPO: n (%) | 16 (48%) | 1 (25%) | 9 (45%) | 9 (47%) | 1 (33%) | 3 (38%) | |
| anti-PR3: n (%) | 17 (52%) | 3 (75%) | 11 (55%) | 10 (53%) | 2 (67%) | 5 (62%) | |
| Histologically proven | 17 (52%) | 1 (25%) | 15 (75%) | 6 (32%) | 1 (33%) | 3 (38%) | |
| Number of relapses | |||||||
| First manifestation | 17 (52%) | 2 (50%) | 9 (45%) | 11 (58%) | 0 | 5 (62%) | |
| Median (IQR) | 0 (0, 2) | 0.5 (0, 1.25) | 1 (0, 1) | 0 (0, 1) | 1 (1, 1.5) | 0 (0, 1) | |
| Mo since first diagnosis: median (IQR) | 2 (0, 52) | 9 (4, 136) | 46 (35, 69) | 1 (0, 48) | 174 (105, 243) | 40 (20, 57) | |
| Berden class: count, (%) | |||||||
| Crescentic | 4 (31%) | 0 (0%) | |||||
| Focal | 2 (15%) | 4 (44%) | |||||
| Mixed | 5 (38%) | 2 (22%) | |||||
| Sclerotic | 0 (0%) | 1 (11%) | |||||
| Too few | 2 (15%) | 1 (11%) | |||||
| Treatment before sample acquisition | |||||||
| Naive | 16 (48%) | 9 (47%) | |||||
| Steroids | 17 (52%) | 10 (53%) | |||||
| BVAS: median (IQR) | 15 (12, 19) | 16 (10, 19) | 0 (0, 0) | 16 (14, 20) | 12 (11, 12) | 0 (0, 0) | |
| BVAS renal subcategory: median (IQR) | 10 (10, 12) | 0 (0, 0) | 0 (0, 0) | 12 (10, 12) | 0 (0, 0) | 0 (0, 0) | |
| Creatinine: [μmmol/l] median (IQR) | 161 (95, 300) | 81 (77, 89) | 111 (82, 164) | 291 (216, 382) | 83 (73, 87) | 116 (90, 173) | |
| CRP [mg/l]: median (IQR) | 20 (6, 46) | 17 (6, 30) | 3 (2, 6) | 12 (6, 27) | 15 (9, 28) | 4 (2, 7) | |
| Proteinuria [g/l]: median (IQR) | 1.21 (0.30, 2.10) | 0.11 (0.09, 0.14) | 0.18 (0.11, 0.47) | 0.75 (0.40, 1.29) | 0.13 (0.07, 0.16) | 0.21 (0.12, 0.51) | |
| Ery dipstick | 3 (3, 3) | 0 (0, 0) | 0 (0, 1) | 0 (0, 0) | 3 (3, 3) | 0 (0, 0) | 0 (0, 1) |
| Active sedimenta | 11 (33%) | 0 | 0 | 0 | 7 (36%) | 0 | 0 |
AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; IQR, interquartile range; ery dipstick, erythrocytes on urinary dipstick analysis; GPA, granulomatosis with polyangiitis; HC, healthy control; MPA, microscopic polyangiitis; MPO, myeloperoxidase; nrAAV, nonrenal active AAV; PR3, proteinase 3; rAAV, active renal AAV; Rem, remission.
a
Presence of acanthocytes on phase-contrast microscopy of urinary sediment.